HbA1c News and Research

RSS

Maternal insulin resistance linked to higher abdominal fat in girls

Girls born to mothers with higher insulin resistance during the third trimester are more likely to have more abdominal fat at age 7, according to research presented at the 28th European Congress of Endocrinology in Prague.

12 May 2026

Why are so many mothers missing diabetes follow-up after childbirth?

A New York City cohort study found that few women with postpartum-onset diabetes received guideline-recommended A1C monitoring over three years. Non-Hispanic Black women and mothers with more children faced lower monitoring rates, while Medicaid coverage was linked to better follow-up.

11 May 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Yoga to help manage obesity-related heart and metabolic risks

The impact of yoga on heart health in obesity is modest, suggesting it as a complementary approach for improving metabolic outcomes in high BMI populations.

27 Apr 2026

Scientists will probe whether processing itself makes ultra-processed foods harmful

A randomized controlled trial protocol will test whether the cardiometabolic risks linked to ultra-processed foods stem from industrial processing, poor nutrient composition, or both. Using four controlled diets, researchers will separate the effects of UPF content from saturated fat, added sugar, and sodium on LDL cholesterol, insulin resistance, and blood pressure.

26 Apr 2026

Real-time CGM transforms blood glucose management in type 2 diabetes

A major clinical trial has found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults living with type 2 diabetes who are treated with basal insulin.

23 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

Prediabetes leaves lasting fat tissue changes after bariatric surgery

Prediabetes may leave a lasting molecular "footprint" on adipose (fat) tissue which appears to make maintaining weight loss after bariatric surgery more difficult, according to new research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

22 Apr 2026

AI predicts retinal age to identify early signs of biological aging

There may be some truth to the saying "the eyes are the window to the soul." Age-related changes are reflected in the retina, the light-sensitive tissue at the back of the eye.

21 Apr 2026

Why heart risk is hard to predict in type 1 diabetes

A European study reveals cardiovascular risk patterns in type 1 diabetes, highlighting the need for tailored prevention strategies to catch complications early.

20 Apr 2026

Genetic variants may reduce effectiveness of popular diabetes drugs

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

12 Apr 2026

Fiber supplement stabilizes blood sugar in gestational diabetes

Dietary fiber supplementation shows potential in managing blood sugar levels and preventing preterm births in pregnancies at risk for gestational diabetes.

1 Apr 2026

New algorithm enables precise subtyping of metabolic liver disease

Metabolic-associated steatotic liver disease (MASLD) is a clinically heterogeneous condition with highly variable outcomes affecting more than 30% individuals globally.

26 Mar 2026

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

A narrative review in Food Science & Nutrition examined studies published from 2000 to 2025 and found that camel milk contains bioactive compounds with potential glycemic, anti-inflammatory, gut, and other health benefits. It also stressed that raw, unpasteurized camel milk poses microbial and zoonotic risks, underscoring that safety remains a key part of the story.

25 Mar 2026